Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study...
Clinical Trial
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage...
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA...
Tivic Reports Third Quarter 2025 Financial Results
Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 /...
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to...
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company...
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -- Dermata plans to launch...
Cenmed and Curavit Announce Strategic Collaboration to Streamline Clinical Trial Kitting and Logistics
Partnership integrates customized kitting, just-in-time operations, and nationwide distribution to accelerate decentralized and hybrid trials NEW BRUNSWICK, NEW JERSEY /...
SAS Clinical Acceleration debuts to modernize clinical trials and accelerate time to market
Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new...
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th – NV-387 is Effective Against H3N2
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding...
Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth
IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook Cantor Notes PRE’s ~$120M Liquidity and 387 BTC...
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024...
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –...
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025
WINNIPEG, MB / ACCESS Newswire / November 13, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company...
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive...
ACMA’s Next-Generation Artificial Intelligence Board Certification for Medical Science Liaisons
New Field Medical Affairs Training Program Redefines Future of Medical Affairs with BCMAS ® Board Certification Program that teaches AI Literacy....
Century Health and Memory Treatment Centers Partner to Unlock Real-World Insights on Alzheimer’s Disease Care Using AI
New treatments for Alzheimer's disease are transforming care for more than 7 million people in the US Memory Treatment Centers...
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
RED BANK, N.J., Nov. 13, 2025 /PRNewswire/ -- Tharimmune, Inc. (Nasdaq: THAR) ("Tharimmune" or the "Company"), a digital asset treasury...
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Session led by neurosurgeon Dr. Fraser Henderson and Hemostemix CEO Thomas Smeenk for the University of Florida's Department of Surgery,...